Researchers at NCI Center for Cancer Research have identified extrachromosomal DNA as a major driver of small cell lung cancer, highlighting a novel biomarker and therapeutic target that could be used to eliminate the most aggressive and shapeshifting SCLC cells. The study was published in Cancer Discovery.
Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).
